The Same Cellular “Software Bug” Affects Cancer, HIV, and Hepatitis Therapies 🔬
In cancer, CAR-T cells exhaust and fail. In HIV, T cells give up the fight. In hepatitis, the immune system surrenders. What unites these challenges? Exhausted immune cells that can’t do their job. Last week, presenting CellRep at the **Longevity Investors Conference** in Gstaad (one of 8 selected globally), I realized how many in the longevity field are attacking this same fundamental problem from different angles.
✨ The Science is Real
The conference brought together true pioneers. Aubrey de Grey shared results from his 1,000-mouse rejuvenation study. David Gobel (Methuselah Foundation co-founder) discussed the field’s evolution. Alex Aliper from Insilico Medicine showcased AI-designed drugs already in Phase II trials. “Joe Betts-LaCroix” (Retro Biosciences, $180M from Sam Altman) demonstrated their three-pathway longevity approach.
Key consensus: Rapamycin remains the only drug with proven longevity results. It works by inhibiting mTORC1, with pulsed dosing maintaining benefits while avoiding side effects—validating our approach at CellRep.
đź’ˇ Some Shared Breakthrough Innovations
Lisa Patel (Istesso) presented mitochondrial inhibitors showing promise across multiple conditions. Marcello Rachlyn (PetMoreTime) is extending dog lifespans 9-26% for Brazilian police forces using rapamycin. Fernando Azevedo Pinheiro (Tomorrow Bio) has cryopreserved 20 people and 10 pets—a “second chance” if future science discovers reversal. Erno Duda (MediPredict) shared their metabolomics analysis transforming health optimization in Budapest.
🎯 Human Enhancement Frontier
A provocative session with @Dr. Ali Ghanem, Dr. Zeynep Vetter, and Dr. Aron D’Souza explored “Human 2.0″—how we enhance ourselves as AI advances. Their discussion challenged us to think beyond lifespan to fundamental human capabilities.
🤝 The Connections
From morning workouts to paddle tennis with investors, every moment built relationships. The gala dinner with Marc P. Bernegger (conference organizer, Maximon – The Longevity Company Builder co-founder) and Gabriele Drigo (NEAUVIA/MATEX LAB) was particularly memorable.
đź”® Looking Forward
We at CellRep are proud to be part of this revolution, using AI to rejuvenate cells without gene editing—debugging aging’s “software” rather than attacking the hardware.
The conference reinforced: we’re not just extending lifespan, we’re redefining aging. The convergence of AI and biotechnology creates unprecedented opportunities to tackle humanity’s oldest challenge.
To everyone in Gstaad—thank you for the insights and inspiration. The journey to longevity escape velocity requires all of us.
The future isn’t just longer—it’s better. And it’s closer than we think.
#Longevity #Biotechnology #CellularReprogramming #HealthTech #Innovation #CellRep
